Studying a new drug for sudden kidney failure in hospitalized patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called QRX3 for people in the hospital with a specific type of sudden kidney failure (acute tubular necrosis). The drug aims to help the kidneys recover, and the study will compare it to usual care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in the hospital as a patient.
- You have acute kidney failure (a sudden loss of kidney function).
- Your kidney doctor has confirmed a type of injury called acute tubular necrosis, or a urine test showed high sodium levels (a sign of that condition).
- You are willing to take part in the study.
- You do not have a high risk of bleeding, no blockage in your urinary tract, and you are not already on regular dialysis for long-term kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (QRX-3) to see if it can slow down or prevent further kidney damage in people with chronic kidney disease. If you are at risk of your kidneys getting worse, this treatment might help keep your kidneys working longer.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This trial tests whether a drug called finerenone can help people recover from acute kidney injury (AKI), a sudden loss of kidney function. It might reduce further kidney damage and improve recovery.
This study tests an investigational drug (RVX000222) to see if it helps people with kidney failure who are on dialysis. The drug is given in two parts and may help improve heart health, which is often a concern for dialysis patients.
This study tests a new medicine, BX-001N, to see if it can prevent kidney damage during and after heart surgery for aortic disease. It is for people with moderate kidney problems who are having planned surgery that stops the heart briefly.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
Hear when a new Acute Renal Failure (ARF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.